Quantum-Si (QSI) CFO Jeffry Keyes Sells $4K of Stock

Quantum-Si CFO Jeffry Keyes Trims Stock Stake

Quantum-Si incorporated Chief Financial Officer Jeffry Keyes disposed of 4,116 shares of the company on June 22, 2026. The transaction took place at a price of $0.96 per share, bringing the total value of the sale to $3,951.36. Insider transactions of this nature offer a look at how executive leadership manages personal equity holdings, though sales do not inherently signal a directional shift in business operations.

A Broader Round of Insider Stock Sales

The sale by Keyes coincided with a flurry of executive transactions across late June 2026. President and CEO Jeffrey Alan Hawkins parted with 11,310 shares on June 22 at $0.96 per share for a total value of $10,857.60, followed by another sale of 11,311 shares on June 23 at $0.90 per share valued at $10,179.90. General Counsel and Corporate Secretary Christian Lapointe also sold 15,588 shares on June 22 at $0.93 per share worth $14,496.84, before returning to sell an additional 7,794 shares on June 23 at $0.90 per share for $7,014.60. Chief Product Officer John Vieceli joined the group on June 23 by selling 15,112 shares at $0.90 per share, totaling $13,600.80.

Quantum-Si Stock Trades Near Recent Lows

Shares of Quantum-Si trade around $0.83, sitting closer to their 52-week low of $0.69 than their upper peak of $3.10. The medical device firm commands a market capitalization of roughly $165.48 million. Because the enterprise is not currently profitable, it lacks a meaningful price-to-earnings ratio to gauge traditional valuation metrics.

Analysts Set New Price Targets

On September 29, 2026, HC Wainwright & Co. reiterated its buy rating on the stock while keeping its price target at $4.00. Across the wider analyst community, three professional opinions contribute to a consensus target mean price of $2.30, with estimates stretching from a low of $1.00 up to a high of $4.00.

Proteomics and Next-Generation Sequencing

Founded in 2013 and headquartered in Branford, Connecticut, Quantum-Si operates as a life sciences enterprise focused on proteomics and next-generation protein sequencing platforms. The organization builds instruments like the Platinum and Platinum Pro systems alongside specialized library preparation kits, sequencing reagents, and cloud-based analysis software designed to automate workflows at the single-molecule level.

Upcoming Financial Milestones

Market participants will gain further visibility into the firm's financial trajectory when Quantum-Si delivers its next earnings report on November 5, 2026. These upcoming disclosures will provide updated context on revenue streams and operational execution for the medical device developer.